STAT stories you may have missed
We break down the newly published data on AstraZeneca’s Covid-19 vaccine candidate.
Exclusive analysis: Trump’s claims that recent Covid-19 infection spikes are due to increased testing are wrong.
Operation Warpspeed lacks necessary transparency, writes my colleague Ed Silverman, in his latest column.
Novartis is providing dozens of drugs to poor countries at cost, but advocates aren’t satisfied.
How HHS’ new Covid-19 data system will really impact the U.S. coronavirus response.
Moderna’s skyhigh valuation is a “depressing indictment of the U.S. response to the pandemic."
A new study untangles the web of patents protecting Abbvie’s cancer drug Imbruvica.
States struggling with the economic impact of the coronavirus pandemic are cutting funding for addiction treatment programs.
Exclusive analysis: Trump’s claims that recent Covid-19 infection spikes are due to increased testing are wrong.
Operation Warpspeed lacks necessary transparency, writes my colleague Ed Silverman, in his latest column.
Novartis is providing dozens of drugs to poor countries at cost, but advocates aren’t satisfied.
How HHS’ new Covid-19 data system will really impact the U.S. coronavirus response.
Moderna’s skyhigh valuation is a “depressing indictment of the U.S. response to the pandemic."
A new study untangles the web of patents protecting Abbvie’s cancer drug Imbruvica.
States struggling with the economic impact of the coronavirus pandemic are cutting funding for addiction treatment programs.
No hay comentarios:
Publicar un comentario